Jaguar Health Inc (NASDAQ:JAGX)’s stock price was down 20.4% during mid-day trading on Thursday . The company traded as low as $1.11 and last traded at $1.21, approximately 962,900 shares changed hands during trading. An increase of 266% from the average daily volume of 263,390 shares. The stock had previously closed at $1.52.
A number of research analysts recently issued reports on JAGX shares. ValuEngine raised Jaguar Health from a “hold” rating to a “buy” rating in a report on Thursday, August 1st. HC Wainwright set a $10.00 target price on Jaguar Health and gave the stock a “buy” rating in a report on Tuesday, July 2nd. Finally, Zacks Investment Research lowered Jaguar Health from a “buy” rating to a “hold” rating in a report on Thursday.
The business has a fifty day moving average of $2.56 and a 200-day moving average of $1.44. The stock has a market capitalization of $5.58 million, a price-to-earnings ratio of -0.01 and a beta of 0.66. The company has a debt-to-equity ratio of 0.02, a current ratio of 0.30 and a quick ratio of 0.18.
Jaguar Health (NASDAQ:JAGX) last released its earnings results on Tuesday, May 21st. The biotechnology company reported ($12.59) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($13.29) by $0.70. The firm had revenue of $1.59 million for the quarter, compared to analyst estimates of $2.20 million. Jaguar Health had a negative return on equity of 372.84% and a negative net margin of 667.59%. As a group, research analysts anticipate that Jaguar Health Inc will post -6.07 EPS for the current year.
In other news, Director James J. Bochnowski bought 180,582 shares of the stock in a transaction that occurred on Tuesday, July 23rd. The shares were purchased at an average cost of $2.00 per share, with a total value of $361,164.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 1.81% of the stock is owned by insiders.
About Jaguar Health (NASDAQ:JAGX)
Jaguar Health, Inc, a commercial stage natural-products pharmaceuticals company, focuses on developing gastrointestinal products for human prescription use and animals worldwide. The company, through its wholly-owned subsidiary, Napo Pharmaceuticals, Inc, focuses on developing and commercializing proprietary human gastrointestinal pharmaceuticals for the global marketplace from plants used traditionally in rainforest areas.
Read More: Why are percentage decliners important?
Receive News & Ratings for Jaguar Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jaguar Health and related companies with MarketBeat.com's FREE daily email newsletter.